HOOKIPA Pharma (HOOK) said Thursday it struck a deal to sell its key assets from its HB-400 program for hepatitis B virus and HB-500 program for human immunodeficiency virus program to Gilead Sciences (GILD) for up to $10 million.
These programs are currently in clinical development, the company said in a regulatory filing. Gilead will not acquire other assets, including its HB-500 phase 1b clinical trial.
HOOKIPA said it will receive $3 million upfront at closing, with up to $7 million due in three phases.
Shares of HOOKIPA rose past 11% in recent trading.
Price: 1.72, Change: +0.20, Percent Change: +13.16
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。